Clinical and Radiographic Evaluation of Dentsply Sirona PrimeTaper Implants

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorAula Dental Avanzada

About this trial

The DS Prime Taper EV dental implant system was recently launched on the implant market by Dentsply Sirona (York, PA, USA).

Dental implant systems are undergoing rapid evolution, ultimately driven by their broad therapeutic indications. As manufacturers strive to keep up with the demands of a growing market, designs are changing faster than clinical evaluation. This means that the time needed to assess medium- and long-term clinical outcomes before designs change again cannot be met.

Clinicians need to have a "real" analysis of the clinical performance of implants before using them. Therefore, reporting of results is necessary to avoid use in patients without proper practical checks even before the recommended 10- and 15-year follow-up periods.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All the patients whom received at least one DS Prime Taper implant.

Disqualifiers

When dental implant surgery is contraindicated.

Trial population

Patients receiving DS Prime Taper dental implant in a private dental office.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Implant Treatment

    Device

    Surgical placement of a DS Prime Taper implant and its posterior prosthesis.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Patients DS Prime Taper1 intervention

Trial outcomes

Primary outcomes

1

Implant Survival Rate

Time of survival of DS Prime Taper dental implant placed

Time frame
through study completion, an average of 1 year
2

Implant Success Rate

Radiological assessment of Marginal Bone Levels around DS Prime Taper implants in function

Time frame
through study completion, an average of 1 year
3

Biological and mechanical complications events

All type of complications that may occur during implant survival

Time frame
through study completion, an average of 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.